Celltrion Applies for Global Phase 3 Clinical Trial of 'Actemra' Biosimilar

[Asia Economy Reporter Hwang Yoon-joo] Celltrion announced on the 17th that it has applied for a Phase 3 clinical trial plan for 'CT-P47,' a biosimilar of the rheumatoid arthritis treatment 'Actemra' (generic name: tocilizumab).

Celltrion began the Phase 1 clinical trial of CT-P47 in July of last year.

The Phase 3 trial is a study comparing the efficacy, safety, pharmacokinetics, and immunogenicity of CT-P47 and Actemra in a total of 448 rheumatoid arthritis patients across Europe.